Mindset Pharma Inc. announced it has selected a subset of representative compounds belonging to its proprietary third family of patent-pending next generation psychedelic compounds to move into in vivo Proof-of-Concept ("PoC") studies. Mindset will continue to advance its diverse portfolio of novel proprietary psilocybin-inspired drug candidate compounds through its rigorous pre-clinical development process, and the company anticipates sharing a comprehensive overview of results from in vivo studies on Mindset patent families 1 and 2 shortly. Management of Mindset wishes to caution readers that any statements regarding its novel psychedelic drug candidate compounds are based on preliminary testing data and the clinical success of such compounds is speculative in nature. For more complete and specific information regarding the Company, its prospects and the risks associated with those prospects, readers should consult the Company's website and other reliable sources.